Positron Emission Tomography/Computed Tomography with <sup>89</sup>Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion.
View/ Open
Date
2018-09ICR Author
Author
Hekman, MCH
Rijpkema, M
Aarntzen, EH
Mulder, SF
Langenhuijsen, JF
Oosterwijk, E
Boerman, OC
Oyen, WJG
Mulders, PFA
Type
Journal Article
Metadata
Show full item recordAbstract
Based on the high expression of carbonic anhydrase IX (CAIX) in 95% of clear cell renal cell carcinoma (ccRCC), the anti-CAIX monoclonal antibody girentuximab can be used for the detection of ccRCC. This clinical study explores the value of <sup>89</sup>Zr-labeled girentuximab positron emission tomography/computed tomography (PET/CT) imaging in diagnostic challenges regarding ccRCC. PET/CT imaging was performed 4 or 5 d after injection of <sup>89</sup>Zr-girentuximab in patients with a primary renal mass (n=16) or a history of ccRCC (n=14). Scans were used for decision making (surgery/active surveillance) in case of indistinct renal masses. All resected PET-positive primary lesions proved to be ccRCC, while no lesion progression was seen in PET-negative masses. In patients suspected of recurrent/metastatic ccRCC, PET/CT with <sup>89</sup>Zr-girentuximab was useful to confirm or exclude ccRCC, evaluate the extent of the disease, and differentiate from other cancers. In this group, <sup>89</sup>Zr-girentuximab PET/CT resulted in a major change in clinical management in five patients (36%), while in three patients (21%) repeat biopsies could be avoided. We conclude that <sup>89</sup>Zr-girentuximab PET/CT is a valuable diagnostic tool that can guide clinical decision making in case of diagnostic dilemmas concerning ccRCC suspicion.Patient summary Positron emission tomography/computed tomography imaging with <sup>89</sup>Zr-girentuximab can be a valuable diagnostic tool to identify clear cell renal cell carcinoma.
Collections
Subject
Humans
Carcinoma, Renal Cell
Kidney Neoplasms
Antibodies, Monoclonal
Antigens, Neoplasm
Radiopharmaceuticals
Diagnosis, Differential
Nephrectomy
Predictive Value of Tests
Decision Support Techniques
Patient Selection
Watchful Waiting
Biomarkers, Tumor
Clinical Decision-Making
Carbonic Anhydrase IX
Positron Emission Tomography Computed Tomography
Research team
Translational Molecular Imaging
Language
eng
Date accepted
2018-04-19
License start date
2018-09
Citation
European urology, 2018, 74 (3), pp. 257 - 260